Seventure Partners invests €3.5m in Domain Therapeutics

Seventure's investments can range between €500,000-10m per round, or up to €20m per company, from early to late stage.

Sofinnova Partners led a €3m round in 2012 for Domain Therapeutics (then Faust Pharmaceuticals), contributing two thirds of the capital. The remainder of the funding was supplied by Auriga Partners.

Six years later, AGF Private Equity, Auriga, Edmond de Rothschild Investment Partners and Sofinnova injected €2.11m into Domain Therapeutics, alongside new investors Alsace Inter Regio Fonds d'Investissement and Alsace Création.

Subsequently, Seventure led a €2m financing round for Domain Therapeutics, contributing half of the fresh capital in 2012. French venture player SODIV also invested in the firm alongside existing shareholders Alsace Inter Regio Fonds d'Investissement, IP Growth, Auriga and the company's chairman.

Company
Founded in 2001 and based in Strasbourg, Domain Therapeutics is a biotechnology company operating in the field of discovery and early development of programmes targeting membrane receptors in central nervous system (CNS) disorders, oncology/immuno-oncology and rare diseases.

People
Seventure Partners – Sébastien Groyer (partner).
Domain Therapeutics – Pascal Neuville (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• France